In any of the human trials performed by (or in collaboration with) Immunophotonics, the investigator will strictly ensure that the study is conducted to full conformance with the principles of the Declaration of Helsinki (and amended in Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996, Edinburgh 2000, Washington 2002, Tokyo 2004, and Seoul 2008) or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual.

Furthermore, it is the responsibility of the investigator to obtain written informed consent from each patient participating in the study or to withdraw from it any time, for any reason. The investigator must assure that patient’s anonymity will be maintained and that their identities are protected from unauthorized parties. Approval from Institutional Review Boards or Ethical Committees must be obtained before any study is started, and should be documented in a letter to the investigator specifying the date on which the Board met and grated the approval. When no local review board exists, the investigator is expected to submit the protocol to a regional Board.